Stayble Therapeutics AB Total Liabilities

Latest as of December 2025: Skr1.70 Million SEK ≈ $182.84K USD

Stayble Therapeutics AB total liabilities. Based on the latest financial reports, Stayble Therapeutics AB (STABL) has total liabilities worth Skr1.70 Million SEK (≈ $182.84K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check STABL cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Stayble Therapeutics AB (2016–2025)

Total liabilities of Stayble Therapeutics AB from 2016 to 2025. This chart illustrates how Stayble Therapeutics AB's total liabilities have evolved over time, based on quarterly financial data.

Stayble Therapeutics AB Competitors by Total Liabilities

The table below lists competitors of Stayble Therapeutics AB ranked by their total liabilities.

Company Country Total Liabilities
Fsport AB
ST:FSPORT
Sweden Skr1.12 Million
Sonovia Ltd
TA:SONO
Israel ILA149.03K
Distribution Finance Capital Holdings PLC
LSE:DFCH
UK GBX872.21 Million
Niraj Ispat Industries Limited
NSE:NIRAJISPAT
India Rs54.63 Million
Polledo S.A.
BA:POLL
Argentina AR$427.53 Million
Nexoptic Technology Corp
V:NXO
Canada CA$2.25 Million
Moovly Media Inc
V:MVY
Canada CA$5.00 Million
Infield Minerals Corp
V:INFD
Canada CA$195.42K

Liability Composition Analysis (2016–2025)

This chart breaks down Stayble Therapeutics AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Stayble Therapeutics AB (STABL) total assets.

Liquidity & Leverage Metrics

Stayble Therapeutics AB Total Liabilities Ratios Explained

Stayble Therapeutics AB total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 3.50 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.25 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.20 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Stayble Therapeutics AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Stayble Therapeutics AB (2016–2025)

The table below shows the annual total liabilities of Stayble Therapeutics AB from 2016 to 2025.

Year Total Liabilities Change
2025-12-31 Skr1.70 Million
≈ $182.84K
-28.73%
2024-12-31 Skr2.38 Million
≈ $256.56K
-54.11%
2023-12-31 Skr5.19 Million
≈ $559.06K
+34.38%
2022-12-31 Skr3.87 Million
≈ $416.03K
+0.90%
2021-12-31 Skr3.83 Million
≈ $412.32K
+56.50%
2020-12-31 Skr2.45 Million
≈ $263.46K
-75.55%
2019-12-31 Skr10.01 Million
≈ $1.08 Million
+429.62%
2018-12-31 Skr1.89 Million
≈ $203.49K
+55.95%
2017-12-31 Skr1.21 Million
≈ $130.48K
+10.22%
2016-12-31 Skr1.10 Million
≈ $118.39K
--

About Stayble Therapeutics AB

ST:STABL Sweden Biotechnology
Market Cap
$1.42 Million
Skr13.19 Million SEK
Market Cap Rank
#30379 Global
#692 in Sweden
Share Price
Skr0.21
Change (1 day)
+0.00%
52-Week Range
Skr0.03 - Skr0.35
All Time High
Skr16.95
About

Stayble Therapeutics AB (publ) a clinical pharmaceutical company, developing an injection-based treatments for disc herniation. It develops STA363, an injection into the disc that targets chronic low back and leg pain. The company was incorporated in 2015 and is based in Gothenburg, Sweden.